Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups
- PMID: 10835439
- DOI: 10.1161/01.str.31.6.1240
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups
Abstract
Background and purpose: Long-term daily aspirin is of benefit in the years after ischemic stroke, and 2 large randomized trials (the Chinese Acute Stroke Trial [CAST] and the International Stroke Trial [IST]), with 20 000 patients in each, have shown that starting daily aspirin promptly in patients with suspected acute ischemic stroke also reduces the immediate risk of further stroke or death in hospital and the overall risk of death or dependency. However, some uncertainty remains about the effects of early aspirin in particular categories of patient with acute stroke.
Methods: To assess the balance of benefits and risks of aspirin in particular categories of patient with acute stroke (eg, the elderly, those without a CT scan, or those with atrial fibrillation), a prospectively planned meta-analysis is presented of the data from 40 000 individual patients from both trials on events that occurred in the hospital during the scheduled treatment period (4 weeks in CAST, 2 weeks in IST), with 10 characteristics used to define 28 subgroups. This represents 99% of the worldwide evidence from randomized trials.
Results: There was a highly significant reduction of 7 per 1000 (SD 1) in recurrent ischemic stroke (320 [1.6%] aspirin versus 457 [2. 3%] control, 2P<0.000001) and a less clearly significant reduction of 4 (SD 2) per 1000 in death without further stroke (5.0% versus 5. 4%, 2P=0.05). Against these benefits, there was an increase of 2 (SD 1) per 1000 in hemorrhagic stroke or hemorrhagic transformation of the original infarct (1.0% versus 0.8%, 2P=0.07) and no apparent effect on further stroke of unknown cause (0.9% versus 0.9%). In total, therefore, there was a net decrease of 9 (SD 3) per 1000 in the overall risk of further stroke or death in hospital (8.2% versus 9.1%, 2P=0.001). For the reduction of one third in recurrent ischemic stroke, subgroup-specific analyses found no significant heterogeneity of the proportional benefit of aspirin (chi(2)(18)=20. 9, NS), even though the overall treatment effect (chi(2)(1)=24.8, 2P<0.000001) was sufficiently large for such subgroup analyses to be statistically informative. The absolute risk among control patients was similar in all 28 subgroups, so the absolute reduction of approximately 7 per 1000 in recurrent ischemic stroke does not differ substantially with respect to age, sex, level of consciousness, atrial fibrillation, CT findings, blood pressure, stroke subtype, or concomitant heparin use. There was no good evidence that the apparent decrease of approximately 4 per 1000 in death without further stroke was reversed in any subgroup or that in any subgroup the increase in hemorrhagic stroke was much larger than the overall average of approximately 2 per 1000. Finally, there was no significant heterogeneity between the reductions in the composite outcome of any further stroke or death (chi(2)(18)=16.5, NS). Among the 9000 patients (22%) randomized without a prior CT scan, aspirin appeared to be of net benefit with no unusual excess of hemorrhagic stroke; moreover, even among the 800 (2%) who had inadvertently been randomized after a hemorrhagic stroke, there was no evidence of net hazard (further stroke or death, 63 aspirin versus 67 control).
Conclusions: Early aspirin is of benefit for a wide range of patients, and its prompt use should be routinely considered for all patients with suspected acute ischemic stroke, mainly to reduce the risk of early recurrence.
Similar articles
-
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.Lancet. 1997 Jun 7;349(9066):1641-9. Lancet. 1997. PMID: 9186381 Clinical Trial.
-
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.Lancet. 1997 May 31;349(9065):1569-81. Lancet. 1997. PMID: 9174558 Clinical Trial.
-
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.JAMA. 2002 Nov 20;288(19):2441-8. doi: 10.1001/jama.288.19.2441. JAMA. 2002. PMID: 12435257
-
[Antithrombotic treatment in acute ischemia stroke].Neurologia. 1995 Dec;10 Suppl 2:48-54. Neurologia. 1995. PMID: 8714450 Review. Spanish.
-
Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):17-25. doi: 10.1136/jnnp.56.1.17. J Neurol Neurosurg Psychiatry. 1993. PMID: 8429318 Free PMC article. Review.
Cited by
-
Observation of the Therapeutic Effect of Dual Antiplatelet Therapy with Aspirin and Clopidogrel on the Incidence, Characteristics, and Outcome in Acute Ischemic Stroke Patients with Cerebral Microbleeds at a Teaching Hospital, China.Int J Gen Med. 2024 May 21;17:2327-2336. doi: 10.2147/IJGM.S459323. eCollection 2024. Int J Gen Med. 2024. PMID: 38803551 Free PMC article.
-
Effect of aspirin on cholesterol crystallization: A potential mechanism for plaque stabilization.Am Heart J Plus. 2022 Jan 4;13:100083. doi: 10.1016/j.ahjo.2021.100083. eCollection 2022 Jan. Am Heart J Plus. 2022. PMID: 38560074 Free PMC article.
-
Efficacy and safety of aspirin antiplatelet therapy within 48 h of symptom onset in patients with acute stroke.World J Clin Cases. 2023 Nov 16;11(32):7814-7821. doi: 10.12998/wjcc.v11.i32.7814. World J Clin Cases. 2023. PMID: 38073696 Free PMC article. Clinical Trial.
-
Risk of secondary stroke subsequent to restarting aspirin in chronic stroke patients suffering from traumatic brain injury in Taiwan.Sci Rep. 2023 May 17;13(1):8001. doi: 10.1038/s41598-023-34986-z. Sci Rep. 2023. PMID: 37198229 Free PMC article.
-
FACTORS ASSOCIATED WITH ORAL INTAKE ABILITY IN PATIENTS WITH ACUTE-STAGE STROKE.J Rehabil Med Clin Commun. 2021 Dec 20;4:2657. doi: 10.2340/20030711-1000078. eCollection 2021. J Rehabil Med Clin Commun. 2021. PMID: 36620126 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous